Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by wyndeweston Apr 19, 2017 9:55pm
253 Views
Post# 26140623

RE:RE:Boehringer North America

RE:RE:Boehringer North AmericaThey do have FDA approval for IPF.  The group test they referred to today is intended to target all types of lung fibrosis. IPF is one small unique segment of lung fibrosis.  Boehringer thinks their approved IPF Drug Nintendab (spelling?) will also work on the many other kinds of lung fibrosis. Best to go to the Boehringer North America web page and read  the announcement in full.  There are a lot of interesting details that most likely pertain to Prometic 4050 as well....
Bullboard Posts